Your browser doesn't support javascript.
loading
Delayed activation of PPAR-ß/δ improves long-term survival in mouse sepsis: effects on organ inflammation and coagulation.
Busch, Daniel; Kapoor, Amar; Rademann, Pia; Hildebrand, Frank; Bahrami, Soheyl; Thiemermann, Christoph; Osuchowski, Marcin F.
Afiliación
  • Busch D; 1 Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Research Center, Vienna, Austria.
  • Kapoor A; 2 Department of General-, Visceral-, Thoracic- and Vascular Surgery, Helios Hanseklinikum Stralsund, Germany.
  • Rademann P; 3 Centre for Translational Medicine and Therapeutics, William Harvey Research Institute, London, UK.
  • Hildebrand F; 1 Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Research Center, Vienna, Austria.
  • Bahrami S; 4 Center for Experimental Medicine, Medical Faculty, University of Cologne, Cologne, Germany.
  • Thiemermann C; 5 Department of Traumatology, RWTH Aachen, Germany.
  • Osuchowski MF; 1 Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Research Center, Vienna, Austria.
Innate Immun ; 24(4): 262-273, 2018 05.
Article en En | MEDLINE | ID: mdl-29697010
Activation of peroxisome proliferator-activated receptor (PPAR)-ß/δ reduces tissue injury in murine endotoxemia. We hypothesized that the PPAR-ß/δ-agonist GW0742 improves long-term outcome after sepsis caused by cecal ligation and puncture (CLP). Fifty-one CD-1 female mice underwent CLP and received either vehicle (control), GW0742 (0.03 mg/kg/injection; five post-CLP i.v. injections), GSK0660 (PPAR-ß/δ-antagonist) or both and were monitored for 28 d. Another 20 CLP mice treated with GW0742 and vehicle were sacrificed 24 h post-CLP to assess coagulopathy. Compared to vehicle, survival of CLP-mice treated with GW0742 was higher by 35% at d 7 and by 50% at d 28. CLP mice treated with GW0742 had 60% higher IFN-γ but circulating monocyte chemoattractant protein-1 and chemokine ligand were lower at 48 h post-CLP. Compared to vehicle, CLP mice treated with GW0742 exhibited a 50% reduction in the circulating plasminogen activator inhibitor-1 associated with an increase in platelet number at 24 h post-CLP (but no changes occurred in anti-thrombin-III, plasminogen, fibrinogen and clotting-times). CLP mice treated with GW0742 exhibited a similar increase in most of the biochemical markers of organ injury/dysfunction (lactate dehydrogenase, alanine aminotransferase, creatine kinase, creatinine, blood urea nitrogen, and triglycerides) measured. Treatment with GW0742 consistently improved long-term survival in septic CD-1 mice by partially modulating the post-CLP systemic cytokine response and coagulation systems.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sepsis / PPAR-beta / PPAR delta Límite: Animals Idioma: En Revista: Innate Immun Asunto de la revista: ALERGIA E IMUNOLOGIA / BACTERIOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sepsis / PPAR-beta / PPAR delta Límite: Animals Idioma: En Revista: Innate Immun Asunto de la revista: ALERGIA E IMUNOLOGIA / BACTERIOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Estados Unidos